Department of Pathology, Harper University Hospital, Wayne State University School of Medicine, and Karmanos Cancer Institute, Detroit, MI 48201, USA.
Hum Pathol. 2010 Apr;41(4):594-601. doi: 10.1016/j.humpath.2009.10.011. Epub 2010 Jan 8.
Although clear cell adenocarcinoma have been described focally mimicking nephrogenic adenoma, we have identified a subset of clear cell adenocarcinoma that diffusely resembles nephrogenic adenoma (nephrogenic adenoma-like clear cell adenocarcinoma). Twelve classic clear cell adenocarcinomas of the bladder and urethra and 7 nephrogenic adenoma-like clear cell adenocarcinomas were compared to 10 nephrogenic adenomas. Classic clear cell adenocarcinomas and nephrogenic adenoma-like clear cell adenocarcinomas comprised 4 men and 15 women. The following features were seen in classic clear cell adenocarcinomas: nephrogenic adenoma-like clear cell adenocarcinomas: predominantly solid pattern (7/12:0/7), marked nuclear pleomorphism (7/12:1/7), prominent nucleoli (5/12:1/7), clear cytoplasm in 50% or greater of tumor (7/12:0/7), and necrosis (8/12:3/7), although the necrosis in nephrogenic adenoma-like clear cell adenocarcinomas was often focal and intraluminal. Both patterns of clear cell adenocarcinomas showed prominent hobnail features, although more pronounced in nephrogenic adenoma-like clear cell adenocarcinomas. Muscularis propria invasion was seen in 5 of 9 classic clear cell adenocarcinomas and 6 of 6 nephrogenic adenoma-like clear cell adenocarcinomas, where evaluable. Classic clear cell adenocarcinoma was associated with urothelial carcinoma (n = 2) and endometriosis (n = 1). The Ki-67 rate in clear cell adenocarcinomas ranged from 10% to 80% compared with 0% to 5% in nephrogenic adenoma. The following antibodies were not helpful in distinguishing nephrogenic adenoma-like clear cell adenocarcinoma from nephrogenic adenoma: CD10, estrogen receptor, p63, high-molecular-weight cytokeratin, and alpha-methylacyl coenzyme-A racemase. PAX2 expression was more frequent in nephrogenic adenoma (89%) compared to both patterns of clear cell adenocarcinoma (29%-32%). The key features discriminating between nephrogenic adenoma-like clear cell adenocarcinoma and nephrogenic adenoma include occasional clear cells, more prominent pleomorphism especially hyperchromatic enlarged nuclei, and extensive muscular invasion. Presence of mitoses and a high rate of Ki-67 expression in lesions resembling nephrogenic adenoma require clinical correlation, close follow-up, and repeat biopsy with more extensive sampling.
虽然已经描述了局灶性类似于肾源性腺瘤的透明细胞腺癌,但我们已经确定了一组弥漫性类似于肾源性腺瘤的透明细胞腺癌(肾源性腺瘤样透明细胞腺癌)。比较了 12 例经典的膀胱和尿道透明细胞腺癌和 7 例肾源性腺瘤样透明细胞腺癌与 10 例肾源性腺瘤。经典的透明细胞腺癌和肾源性腺瘤样透明细胞腺癌包括 4 名男性和 15 名女性。经典的透明细胞腺癌和肾源性腺瘤样透明细胞腺癌具有以下特征:透明细胞腺癌:弥漫性实性模式(7/12:0/7)、明显的核多形性(7/12:1/7)、显著的核仁(5/12:1/7)、肿瘤中 50%或更多的透明细胞质(7/12:0/7)和坏死(8/12:3/7),尽管肾源性腺瘤样透明细胞腺癌中的坏死通常是局灶性和腔内的。两种透明细胞腺癌模式均表现出明显的钉突特征,尽管肾源性腺瘤样透明细胞腺癌更为明显。在可评估的 9 例经典透明细胞腺癌中的 5 例和 6 例肾源性腺瘤样透明细胞腺癌中均观察到固有肌层浸润。经典的透明细胞腺癌与尿路上皮癌(n=2)和子宫内膜异位症(n=1)相关。透明细胞腺癌的 Ki-67 率范围为 10%至 80%,而肾源性腺瘤为 0%至 5%。以下抗体对鉴别肾源性腺瘤样透明细胞腺癌和肾源性腺瘤无帮助:CD10、雌激素受体、p63、高分子量细胞角蛋白和α-甲基酰基辅酶 A 消旋酶。与两种透明细胞腺癌(29%-32%)相比,PAX2 表达在肾源性腺瘤中更为频繁(89%)。鉴别肾源性腺瘤样透明细胞腺癌和肾源性腺瘤的关键特征包括偶尔出现透明细胞、更明显的多形性,尤其是核增大、染色质深染和核仁明显、广泛的肌层浸润。类似于肾源性腺瘤的病变中存在有丝分裂和 Ki-67 表达率高需要临床相关性、密切随访和重复活检,以进行更广泛的取样。